Search

How can get structured therapies in metastatic cancer a source for detecting tumor-associated systems-biological processes as adjustable sizes available for biomodulatory therapies? A therapy-derived methodological approach to explore tumor-associated systems biology should be explicated and developed by means of analyses of recently -published biomodulatory therapy approaches introducing combined anti--inflammatory; angiostatic; and immunomodulatory therapy in the treatment for advanced chemorefractory tumors of quite different origin. Biomodulatory therapy approaches in tumors intend to develop systems-terms that provide a basis for broadening therapy-relevant capacities by regulating biological systems processes for tumor control. Combined targeted therapies of tumor-associated wound healing mechanisms, namely inflammation and neoangiogenesis, have shown that – using an approach for understanding systems biology as adjustable size – we may break through the barrier of complexity of tumor-stroma-interactions in a therapeutically relevant way. Targeting the tumor systems΄ topology of aggregated action effects (inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects) may open up the perspective of individualized tumor therapy. [ABSTRACT FROM AUTHOR]

So far, tumors have been assumed to defy experimental therapeutic access from inside in a comprehensive and reconstructive way (systems view) and to only comply with reductionist knowledge with regard to biochemical pathways. Our main aim was the uncovering and reconstruction of tumor systems structures mediating tumor-associated inflammation (eight phase II trials, two of them randomized). Thus, we comparatively analyzed anti-inflammatory activities and clinical response induced by continuously administered biomodulatory treatment modules (module M: metronomic low-dose chemotherapy; module A: pioglitazone plus etoricoxib; module A+M; module A+M/+: plus second transcriptional modulator [interferon-alpha or dexamethasone]) in the metastatic stages of different types of tumors (266 patients; 54% systemically pre-treated; metastatic melanoma, sarcoma, renal clear cell carcinoma, castration-resistent prostate cancer, gastric cancer, and Langerhans΄ cell histiocytosis). Tumor-specific and stage-specific therapeutic accessibility of inflammation-related processes to induce response in all tumor types indicate a constitutive spin-off of new systems functions during metastatic processes. Furthermore, this accessibility shows the differential integration of inflammation into the context-dependent `living world΄ of tumor compartments that is marked by tumor-specific and subtype-specific rationalization processes: Inflammation-related activities are communicatively promoted and differentially adapted during tumor evolution. Empirically, differences may be detected in the modalities of developing evolutionary systems and in the acquired functional impact of inflammation-related systems. Biomodulatory therapies, administered as fixed modules, may contribute to the discovery and understanding of novel regulatory systems in tumor biology. This study highlights the claim for validity of therapeutic inflammation control as an important prerequisite for tumor control on the basis of action-relevant yes or no statements that generate facts on-site in tumors via biomodulatory therapy modules. [ABSTRACT FROM AUTHOR]

Intraventricular hemorrhage (IVH) is defined as bleeding within the ventricular system IVH can occur as a primary event or in association with intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), or traumatic brain injury (TBI) ˵Primary IVH″ is a rare occurrence in which hemorrhage is confined only to the ventricular system ˵Secondary IVH″ denotes a hemorrhage that originates from parenchyma or subarachnoid space and extends into the ventricles IVH with ICH [ABSTRACT FROM AUTHOR]